<!doctype html>
<html lang="en">
  <head>
    <meta charset="utf-8" />
    <meta name="viewport" content="width=device-width, initial-scale=1" />
    <title>Press Release Biocartis NV: Biocartis Receives FDA Approval for the Idylla™ CDx MSI Test</title>
    <meta name="description" content="PRESS RELEASE - 09/15/2025, 09:00 AM EDT Biocartis Receives FDA Approval for the Idylla™ CDx MSI Test First-ever fully automated, sample-to-result, cartridge-based companion diagnostic test approved in the US for colorec; The Idylla™ CDx MSI Test aids in identifying eligible microsatellite instability-high (MSI-H) colorectal cancer (CRC) patients, who may benefit from treatment with OPDIVO® (nivolumab) alone, or in combination with YERVOY; The Test runs in a single-use cartridge, requiring less than three minutes of hands-on-time and delivering straightforward results in under three hours." />
    <link rel="alternate" type="application/rss+xml" title="Daily Finance Newsletter" href="https://suavir600.github.io/newsletter/feed.xml" />
    <style>
:root{--bg:#0b0f19;--fg:#e8ecf2;--muted:#93a1b1;--card:#121826;--accent:#4f8cff}
*{box-sizing:border-box} body{margin:0;background:var(--bg);color:var(--fg);font:16px/1.55 system-ui,-apple-system,Segoe UI,Roboto,Ubuntu}
a{color:var(--accent);text-decoration:none} a:hover{text-decoration:underline}
.container{max-width:980px;margin:0 auto;padding:20px}
.nav{display:flex;align-items:center;justify-content:space-between;margin-bottom:20px}
.brand{font-weight:700} .muted{color:var(--muted)}
.grid{display:grid;grid-template-columns:repeat(auto-fill,minmax(280px,1fr));gap:16px}
.card{background:var(--card);border-radius:16px;padding:16px;box-shadow:0 6px 20px rgba(0,0,0,.25)}
.card h3{margin:0 0 8px 0;font-size:1.05rem}
.badge{display:inline-block;background:#1c2335;color:#c0cad8;padding:.2rem .5rem;border-radius:999px;font-size:.75rem;margin-right:.4rem}
.btn{display:inline-block;background:var(--accent);color:#fff;padding:.5rem .75rem;border-radius:10px;font-weight:600}
.btn-outline{background:transparent;border:1px solid var(--accent);color:var(--accent)}
.list ul{margin:.5rem 0 0 1.2rem}
.footer{margin-top:36px;color:var(--muted);font-size:.9rem;text-align:center}
hr{border:none;border-top:1px solid #223; margin:16px 0}
</style>
  </head>
  <body>
    <div class="container">
      <div class="nav">
        <div class="brand"><a href="https://suavir600.github.io/newsletter">Daily Finance Newsletter</a></div>
        <div class="muted">5–7 key bullets per story</div>
      </div>
      
<h1>Press Release Biocartis NV: Biocartis Receives FDA Approval for the Idylla™ CDx MSI Test</h1>
<div class="muted">2025-09-15 13:00:00+00:00</div>
<hr />
<div class="list"><ul>
  <li>PRESS RELEASE - 09/15/2025, 09:00 AM EDT Biocartis Receives FDA Approval for the Idylla™ CDx MSI Test First-ever fully automated, sample-to-result, cartridge-based companion diagnostic test approved in the US for colorec</li><li>The Idylla™ CDx MSI Test aids in identifying eligible microsatellite instability-high (MSI-H) colorectal cancer (CRC) patients, who may benefit from treatment with OPDIVO® (nivolumab) alone, or in combination with YERVOY</li><li>The Test runs in a single-use cartridge, requiring less than three minutes of hands-on-time and delivering straightforward results in under three hours.</li><li>“Achieving FDA approval for our Idylla™ CDx MSI Test represents a key milestone for Biocartis,&quot; said Michael Korn, M.D., Chief Medical and Scientific Officer at Biocartis.</li><li>With its speed, accuracy, and automation, the Idylla™ CDx MSI Test offers a powerful solution that enables clinicians to make timely, confident and data-driven treatment decisions when every moment counts.”</li><li>“It underscores our commitment to helping oncology patients receive the right therapy without delay and the recent CheckMate-8HW data reinforce the critical importance of accurate MSI-H/dMMR testing in colorectal cancer.</li><li>“The approval of this new MSI companion diagnostic for patients with colorectal cancer is a meaningful achievement from our collaboration with Biocartis and a strong reflection of our Precision Medicine strategy at Brist</li>
</ul></div>
<div style="margin-top:12px">
  <a class="btn-outline" href="https://finance.yahoo.com/news/press-release-biocartis-nv-biocartis-130000684.html" target="_blank" rel="noopener">Original</a>
  <a class="btn" href="https://twitter.com/intent/tweet?text=Press+Release+Biocartis+NV%3A+Biocartis+Receives+FDA+Approval+for+the+Idylla%E2%84%A2+CDx+MSI+Test%0A%E2%80%A2+PRESS+RELEASE+-+09%2F15%2F2025%2C+09%3A00+AM+EDT+Biocartis+Receives+FDA+Approval+for+the+Idylla%E2%84%A2+CDx+MSI+Test+First-ever+fully+automated%2C+sample-to-result%2C+cartridge-based%E2%80%A6%0Ahttps%3A%2F%2Fsuavir600.github.io%2Fnewsletter%2Farticles%2Fpress-release-biocartis-nv-biocartis-receives-fda-approval-for-the-idylla-cdx-ms%2F" target="_blank" rel="noopener">Share on X</a>
</div>

      <div class="footer">© 2025 · Built from digest_5bullets.md</div>
    </div>
  </body>
</html>